<?xml version="1.0" encoding="UTF-8"?>
<p>The Chinese companies hope that the government can implement compulsory licenses to improve their situation. In their opinion, if the country issues compulsory licenses, the generic ARV drugs they manufacture can be exported, which will expand the countryâ€™s production capacity and further reduce the cost of the ARV drugs. For instance, the price of lamivudine (3TC) could be reduced to one-tenth of the current price in China and nevirapine to one-tenth of its international price. Trizivir would only cost 1,000 Chinese RMB per year per person, which is two-fifths of the lowest international price. The companies promise to provide free ARV drugs for the national treatment program once they gain access to the international market [
 <xref ref-type="bibr" rid="CR38">38</xref>].
</p>
